RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 Metabolic Syndrome Elevates Risk of Microalbuminuria despite BP Control
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 18
SP 13
OP 13
DO 10.1177/155989771418007
UL http://mdc.sagepub.com/content/14/18/13.1.abstract
AB Fimasartan reduced blood pressure (BP) and albumin-creatinine ratio (ACR) in patients with or without metabolic syndrome; however, patients with metabolic syndrome at baseline and 3 months were at a greater risk of elevated ACR at 1 year. This article presents 3-month and 1-year data from a 3-year multicenter study designed to evaluate the effect of early correction of metabolic syndrome on organ damage for patients with hypertension [K-METS]. The design of this study has been published [Kim C et al. Pulse 2013].